NCT07346196 2026-01-20
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
University of Chicago
Phase 2 Not yet recruiting
Clinical Trials
19 trialsNCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06904300 2025-06-05
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03292822 2024-06-20
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
Cairo University
Phase 1 Completed
NCT01015222 2022-11-23
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT02630199 2022-06-15
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
Phase 1 Completed
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT00936702 2017-03-21
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00201734 2016-09-23
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT00731861 2014-09-11
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
Indiana University
Phase 1 Completed
NCT01235897 2014-04-17
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Completed
NCT00360360 2013-12-04
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01031212 2013-05-13
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
University of California, San Francisco
Phase 1 Withdrawn
NCT00193596 2013-05-03
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 3 Completed